The DOI matches its Crossref record.
Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan
Abstract
That sumatriptan tablets are effective and well tolerated in the acute treatment of migraine has been established, but the relationship between dose and efficacy has not been adequately defined to date in clinical trials. This multinational double‐blind trial (N=1003) in which patients treated up to three migraine attacks with sumatriptan 25 mg, 50 mg, 100 mg, or placebo, with a second independently randomized dose for headache recurrence, evaluated the efficacy and tolerability of three doses of sumatriptan. The results demonstrate that all doses of sumatriptan were superior ( P <0.05) to placebo in reducing moderate or severe predose headache to mild or no headache 4 hours postdose for each of the three treated attacks; sumatriptan 50 mg and 100 mg were each superior ( P <0.05) to sumatiptan 25 mg 4 hours postdose for two of three attacks. Sumatriptan (all doses) was similarly effective at relieving nausea and photophobia or phonophobia or both and at reducing clinical disability. Headache recurrence was experienced by similar proportions of patients across treatment groups (35% to 48% after placebo; 26% to 39% after sumatriptan). Relief of recurrent headache 2 hours after the second dose of study medication occurred in greater percentages of patients using any dose of sumatriptan compared with patients using placebo to treat recurrence. The incidence of adverse events with 25‐mg and 50‐mg sumatriptan tablets was similar to the incidence with placebo and lower than the incidence with 100‐mg sumatriptan tablets. These data provide the first demonstration from a large well‐controlled clinical trial that both the 50‐ and 100‐mg doses are more effective than the 25‐mg dose and that the 50‐mg dose is associated with a lower incidence of adverse events than the 100‐mg dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Ferrari, M., Goadsby, P., Roon, K., & Lipton, R. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00404.x · Cited by 605
Triptans in Migraine: A Comparative Review of Pharmacology, Pharmacokinetics and Efficacy
Tfelt-Hansen, P., De Vries, P., & Saxena, P. R. (2000) · Drugs · doi:10.2165/00003495-200060060-00003 · Cited by 529
Ergotamine in the acute treatment of migraine: A review and European consensus
Tfelt-Hansen, P. (2000) · Brain · doi:10.1093/brain/123.1.9 · Cited by 393
Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Metadata
- Authors
- Pfaffenrath, V., Cunin, G., Sjonell, G., & Prendergast, S.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 1998-03
- Volume
- 38
- Issue
- 3
- Pages
- 184-190
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W1984136690
- Cited by
- 184
- References
- 0
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan. https://app.cochat.ai/papers/10.1046/j.1526-4610.1998.3803184.x
- The paper
- Pfaffenrath, V., Cunin, G., Sjonell, G., & Prendergast, S. (1998). Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan. Headache: The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.1998.3803184.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.